Aligos Enters into an Exclusive License and Research Collaboration Agreement With Merck

Aligos Therapeutics, Inc. announced that it has entered into an exclusive license and research collaboration agreement with Merck, known as MSD outside of the United States and Canada, under which Merck and Aligos will apply Aligos’ oligonucleotide platform technology to discover, research, optimize and develop oligonucleotides directed against a non-alcoholic steatohepatitis (NASH) target and up to one additional target of interest in the cardiometabolic/fibrosis space.